This article was downloaded by:

On: 29 January 2011

Access details: Access Details: Free Access

Publisher Taylor & Francis

Informa Ltd Registered in England and Wales Registered Number: 1072954 Registered office: Mortimer House, 37-41 Mortimer Street, London W1T 3JH, UK



Phosphorus, Sulfur, and Silicon and the Related Elements

Publication details, including instructions for authors and subscription information: http://www.informaworld.com/smpp/title~content=t713618290

Asymmetric Synthesis of Biologically Active Compounds Bearing a Chiral Sulfinyl Group

Noureddine Khiar^a; Inmaculada Fernandez^a; Felipe Alcudia^a

^a Dpto. de Q. Orgánica y Farmacéutica, Fac. de Farmacia, Sevilla, SPAIN

To cite this Article Khiar, Noureddine, Fernandez, Inmaculada and Alcudia, Felipe (1993) 'Asymmetric Synthesis of Biologically Active Compounds Bearing a Chiral Sulfinyl Group', Phosphorus, Sulfur, and Silicon and the Related Elements, 74: 1, 405-406

To link to this Article: DOI: 10.1080/10426509308038137 URL: http://dx.doi.org/10.1080/10426509308038137

PLEASE SCROLL DOWN FOR ARTICLE

Full terms and conditions of use: http://www.informaworld.com/terms-and-conditions-of-access.pdf

This article may be used for research, teaching and private study purposes. Any substantial or systematic reproduction, re-distribution, re-selling, loan or sub-licensing, systematic supply or distribution in any form to anyone is expressly forbidden.

The publisher does not give any warranty express or implied or make any representation that the contents will be complete or accurate or up to date. The accuracy of any instructions, formulae and drug doses should be independently verified with primary sources. The publisher shall not be liable for any loss, actions, claims, proceedings, demand or costs or damages whatsoever or howsoever caused arising directly or indirectly in connection with or arising out of the use of this material.

Phosphorus, Sulfur, and Silicon, 1993, Vol. 74, pp. 405-406 © 1993 Gordon and Breach Science Publishers S.A. Reprints available directly from the publisher Printed in the United States of America Photocopying permitted by license only

ASYMMETRIC SYNTHESIS OF BIOLOGICALLY ACTIVE COMPOUNDS BEARING A CHIRAL SULFINYL GROUP.

NOUREDDINE KHIAR, INMACULADA FERNANDEZ AND FELIPE ALCUDIA. Dpto. de Q. Orgánica y Farmacéutica, Fac. de Farmacia, Sevilla, SPAIN.

Abstract The asymmetric synthesis of $\mathfrak{Z}(\underline{R}_{C},\underline{R}_{S})$ and $\mathfrak{Z}(\underline{S}_{C},\underline{R}_{S})$, important intermediates in the synthesis of optically pure Sparsomycin analogs, is discussed. The enantioselective synthesis of both isomers, \underline{R} and \underline{S} , of Oxisuran and three of their bioisosters is also described. In both strategies o.p. methanesulfinate esters of DAG were used as starting material.

INTRODUCTION

The utility of o.a. sulfoxides as auxiliaries in highly asymmetric synthesis is now well documented. Additionally, chiral nonracemic alkylsulfoxides occur in a variety of biologically active molecules such as: Sparsomycin 2a , Oxisuran and analogs 2b , Carpetimycin 2c and the potassium channel activator RP49356.

RESULTS AND DISCUSSION

In this communication we present our preliminary results on the asymmetric synthesis of N-protected $\mathfrak{Z}(\underline{R}_C,\underline{S}_S)$ and $\mathfrak{Z}(\underline{S}_C,\underline{R}_S)$, important intermediates in the synthesis of Sparsomycin analogs, and the enantioselective synthesis of both \underline{R} and \underline{S} isomers of Oxisurane and three of their bioisosters.

Asymmetric synthesis of N-protected $\underline{3}(\underline{R}_C,\underline{S}_S)$ and $\underline{3}(\underline{S}_C,\underline{R}_S)$. Sparsomycin $\underline{1}$ has received considerable attention because of its biological

activity against various tumors, bacteria, fungi and viruses.

From a retrosynthetic analysis, sparsomycin 1 can be viewed as an

amide consisting of β -(6-methyluracyl)acrylic acid 2 and the chiral amine 3.

SCHEME 1 Retrosynthetic scheme of Sparsomycin 1.

The acid 2 is easily obtained from the commercial available 6-methyluracil. More challenging is the synthesis of the hydroxyamine 3. Our asymmetric synthesis of N-protected $3(\underline{R}_{\underline{C}},\underline{S}_{\underline{S}})$ and $3(\underline{S}_{\underline{C}},\underline{R}_{\underline{S}})$ was achieved by combining two new methodologies that we have recently developped: (i) The synthesis of o.p. \underline{R} and \underline{S} methanesulfinates of DAG (\underline{AR} and \underline{AS}), Fig. 1, and (ii) The synthesis of 3-oxazolines 5, Fig. 1.

FIGURE 1 Methanesulfinates of DAG, 4R and 4S, and 3-oxazolines, 5.

Enantioselective synthesis of R and S Oxisuran and bioisosters. The Oxisuran G is a synthetic immunosuppressive drug used in organ and tissue transplants to supress cell-mediated immunity without inhibiting humoral antibody formation.

Optically active oxisuran , $\underline{6R}$ and $\underline{6S}$, and bioisosters, $\underline{7}-\underline{9}(\underline{R}$ and $\underline{S})$, can be obtained from the enolate of the corresponding aryl methyl ketone and the adequate methanesulfinate ester of DAG, $\underline{4R}$ or $\underline{4S}$, Scheme 2. In order to avoid epimerization at sulfur, the N,N-dimethylhydrazone of the starting ketones were used.

Oxisuran: Ar = 2-Pyr
$$\stackrel{(R)}{(S)}$$
 $X = 0$; $Y = 0$ $X = 0$; $Y = 0$ $X = 0$; $Y = 0$ $Y = 0$

SCHEME 2 Retrosynthetic scheme of o.p. Oxisuran and bioisosters.

REFERENCES

- 1. (a) M.R. Barbachyn and C.R. Johnson, <u>Asymmetric Synthesis</u> (J.D.Morrison Ed., Academic Press, New York, 1984), vol. 4, p. 227; (b) F. Davis, J.R. Kern, L.J. Kurtz and J.R. Pfister, J.Am.Chem.Soc., 110, 7873 (1988).
- Kern, L.J. Kurtz and J.R. Pfister, J.Am.Chem.Soc., 110, 7873 (1988).

 2. (a) P. Helquist and M.S. Shekhani, J.Am.Chem.Soc., 101, 1057 (1979);
 (b) G. Briziarelli, D. Abrutyn, J.A. Tornaben and E. Schwartz, Toxicol.

 Appl.Pharmacol., 36, 49 (1976); (c) T. Iimori, Y. Takahashi, T. Izawa,
 S. Kobayashi and M. Ohmo, J.Am.Chem.Soc., 105, 1965 (1983); (d) D.W.

 Roberetson and M.I. Steimberg, Annual Reports in Medicinal Chemistry
 (R.C. Allen Ed., Academic Press, San Diego, 1989), p. 24.